Feature Transition moves into late-stage drug development By Len Zehr Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005... March 18, 2014